Department of Neurology, Shaoxing People's Hospital, 312000 Shaoxing, Zhejiang, China.
Department of Radiology, Shaoxing Seventh People's Hospital (Affiliated Mental Health Center, Medical College of Shaoxing University), 312000 Shaoxing, Zhejiang, China.
Actas Esp Psiquiatr. 2024 Apr;52(2):161-171. doi: 10.62641/aep.v52i2.1552.
Alzheimer's disease (AD) is the leading cause of dementia, resulting in impairments in memory, cognition, decision-making, and social skills. Thus, accurate preclinical diagnosis of Alzheimer's disease is paramount. The identification of biomarkers for Alzheimer's disease through magnetic resonance spectroscopy (MRS) represents a novel adjunctive diagnostic approach.
This study conducted a meta-analysis of the diagnostic results of this technology to explore its feasibility and accuracy.
PubMed, Cochrane Library, EMBASE, and Web of Science databases were searched without restrictions, with the search period extending up to July 31, 2022. The search strategy employed a combination of subject headings and keywords. All retrieved documents underwent screening by two researchers, who selected them for meta-analysis. The included literature was analyzed using Review Manager 5.4 software, with corresponding bias maps, forest plots, and summary receiver operating characteristic (SROC) curves generated and analyzed.
A total of 344 articles were retrieved initially, with 11 articles meeting the criteria for inclusion in the analysis. The analysis encompassed data from approximately 1766 patients. In the forest plot, both sensitivity (95% CI) and specificity (95% CI) approached 1. Examining the true positive rate, false positive rate, true negative rate, and false negative rate, all studies on the summary receiver operating characteristic (SROC) curve clustered in the upper left quadrant, suggesting a very high accuracy of biomarkers detected by MRS for diagnosing Alzheimer's disease.
The detection of biomarkers by MRS demonstrates feasibility and high accuracy in diagnosing AD. This technology holds promise for widespread adoption in the clinical diagnosis of AD in the future.
阿尔茨海默病（AD）是痴呆的主要原因，导致记忆力、认知、决策和社交技能受损。因此，准确的 AD 临床前诊断至关重要。磁共振波谱（MRS）通过识别 AD 的生物标志物代表了一种新的辅助诊断方法。
本研究对这项技术的诊断结果进行了荟萃分析，以探讨其可行性和准确性。
无限制地检索 PubMed、Cochrane Library、EMBASE 和 Web of Science 数据库，检索时间截至 2022 年 7 月 31 日。检索策略采用主题词和关键词的组合。两名研究人员对所有检索到的文件进行筛选，选择符合条件的文献进行荟萃分析。使用 Review Manager 5.4 软件对纳入文献进行分析，生成并分析相应的偏倚图、森林图和综合受试者工作特征（SROC）曲线。
最初检索到 344 篇文章，其中 11 篇文章符合纳入分析的标准。分析纳入了大约 1766 名患者的数据。在森林图中，敏感性（95%CI）和特异性（95%CI）均接近 1。从真阳性率、假阳性率、真阴性率和假阴性率来看，SROC 曲线的所有研究均集中在左上角，表明 MRS 检测到的生物标志物诊断 AD 的准确性非常高。
MRS 检测生物标志物在 AD 诊断中具有可行性和高准确性。这项技术有望在未来广泛应用于 AD 的临床诊断。
